Trial Profile
A randomized, double-blind, placebo-controlled, olanzapine-referenced, parallel group safety, efficacy, and tolerability study of SCA-136 [vabicaserin] in subjects with acute exacerbations of schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2015
Price :
$35
*
At a glance
- Drugs Vabicaserin (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Wyeth
- 07 Dec 2007 Status changed from in progress to completed.
- 05 Nov 2006 New trial record.